Apellis Pharmaceuticals (NASDAQ:APLS) is a biopharmaceutical company dedicated to developing pioneering therapies to treat a broad range of debilitating diseases. The company focuses primarily on advancing targeted C3 therapies, aiming to address critical unmet medical needs in areas such as hematology, ophthalmology, and nephrology. Apellis has a robust pipeline of drug candidates in various stages of clinical development, with an emphasis on bringing innovative solutions to patients suffering from rare and serious conditions. Their flagship projects include novel treatments for paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), and other chronic disorders. Through rigorous research and development, Apellis strives to unlock new possibilities in medical treatment, aiming to improve the lives of patients around the globe.